← All trials
NCT05378763
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2022
- Primary completion
- Dec 25, 2027
- Completion date
- Dec 25, 2028
- First posted
- May 18, 2022
- Last posted
- Jun 14, 2022
- Enrollment
- 268
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spectrum PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.